SCHEMBL25605744

SCHEMBL25605744

CC1CCN(C2CC3(C2)CN(C2CCN(C(=O)C(C)C)CC2)C3)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ CYP3A4 P08684 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44
▸ KDM4E B2RXH2 2/20 0.40
▸ POLB P06746 2/20 0.39
▸ CHRM1 P11229 2/20 0.38
▸ CHRM2 P08172 1/20 0.38
▸ GAA P10253 1/20 0.37
▸ HRH3 Q9Y5N1 2/20 0.36
▸ HPGD P15428 1/20 0.36
▸ L3MBTL3 Q96JM7 2/20 0.33
▸ L3MBTL1 Q9Y468 2/20 0.33
▸ ADRA1A P35348 1/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ MBTD1 Q05BQ5 1/20 0.33
▸ TP53BP1 Q12888 1/20 0.33
▸ L3MBTL4 Q8NA19 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25605727 0.92 ALDH1A1 (0.41) ALDH1A1MEN1KMT2ACYP3A4CYP2C19
SCHEMBL25600527 0.88 OPRL1 (0.38) CYP3A4CYP2C19CHRM1CHRM2HRH3
SCHEMBL18267300 0.87 ALDH1A1 (0.58) ALDH1A1MEN1KMT2ACYP3A4CYP2C19
SCHEMBL25604665 0.87 ALDH1A1 (0.58) ALDH1A1MEN1KMT2ACYP3A4CYP2C19
SCHEMBL25600532 0.85 CYP3A4 (0.35) ALDH1A1MEN1KMT2ACYP3A4CYP2C19
SCHEMBL25600531 0.85 CHRM1 (0.38) ALDH1A1MEN1KMT2ACYP3A4CYP2C19
SCHEMBL25600528 0.83 HRH3 (0.37) CYP3A4CYP2C19CHRM1CHRM2HRH3
SCHEMBL25600526 0.80 OPRL1 (0.34) CHRM1HRH3
SCHEMBL25600327 0.80 OPRL1 (0.36) CHRM1CHRM2HRH3
SCHEMBL25605712 0.79 CHRM4 (0.42) ALDH1A1MEN1KMT2AKDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230173078-A1 SMARCA DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-06-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230173078-A1 SMARCA DEGRADERS AND USES THEREOF SMARCA1, SMARCA2, SMARCC2 ALDH1A1 2230/4885MEN1 2085/4885KMT2A 73/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback